Abdel-Haq B, Magagna A, Favilla S, Salvetti A
Department of Systemic Therapeutic Medicine, 1st Medical Clinic, University of Pisa, Italy.
Int J Clin Pharmacol Ther Toxicol. 1987 Nov;25(11):598-600.
To evaluate whether imidazole salicylate, a recently developed NSAID, can interfere with the antihypertensive effect of atenolol and to compare its action with that of indomethacin, 9 essential hypertensives, while on prolonged (more than 1 month) treatment with atenolol (100 mg qd) received, according to a double-blind cross-over study, imidazole salicylate (750 mg t.i.d.) or indomethacin (50 mg b.i.d. plus a placebo tablet) for 1 week, reverting the treatment after a 2-week wash-out period. While indomethacin addition significantly increased blood pressure, when compared to atenolol alone, imidazole salicylate did not change it. These data show that imidazole salicylate, unlike indomethacin, does not reduce the antihypertensive effect of atenolol.
为评估近期研发的非甾体抗炎药咪唑水杨酸酯是否会干扰阿替洛尔的降压效果,并将其作用与吲哚美辛进行比较,9名原发性高血压患者在接受阿替洛尔(100mg,每日一次)长期(超过1个月)治疗期间,根据双盲交叉研究,接受了为期1周的咪唑水杨酸酯(750mg,每日三次)或吲哚美辛(50mg,每日两次加一片安慰剂)治疗,在为期2周的洗脱期后更换治疗药物。与单独使用阿替洛尔相比,添加吲哚美辛会显著升高血压,而咪唑水杨酸酯则不会改变血压。这些数据表明,与吲哚美辛不同,咪唑水杨酸酯不会降低阿替洛尔的降压效果。